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Abstract
Purpose – This paper aims to explore effective supply chain principles, through the theory of transaction

cost economics, as measures to improve current contingency pharmaceutical item shortfalls in the Air Force
Medical Service (AFMS) Contingency Pharmaceutical Programme.
Design/methodology/approach – In this research, AFMS contingency pharmaceutical data was
collected from various databases, including the Joint Medical Asset Repository, Medical Contingency
Requirements Workﬂow and the Medical Requirements List. Through the methodology of cost-beneﬁt
analysis, alternative sourcing and fulﬁlment practices are evaluated.
Findings – The ﬁndings of this research indicate that the application of centralized purchasing principles,
in an effort to leverage prime vendor contract ﬁll rates for shortage items, can lead to 12%–17% increases in
pharmaceutical material availability across the programme.
Originality/value – This research clearly shows that consolidating demand for shortage items across
Active Duty War Reserve Material assemblages, though applications of centralized purchasing principles
that leverage prime vendor contract ﬁll rates, can lead to substantial increases in material availability at costs
that justify the calculated beneﬁts.
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Introduction
Forecasts for the year 2020 project that supply chain expenses will become the largest
expenditure for US health-care organizations, commanding more budgetary requirements
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than the previous top expense of labor (Paavola, 2019). This means that the materials which
allow a health care facility to function could now attract more attention than the medical
professionals who provide the actual service of health care. At the same time, organizations
are experiencing increasing costs across the entire spectrum of health-care providers which
are further cutting into proﬁt margins (Paavola, 2019). In a strategic effort to increase
performance outcomes, organizations are shifting focus to the improvement of supply chain
management as an efﬁciency driver. This information has health-care leaders focussing on
practices and policies to extract value and minimize waste from supply chain practices.
Practices such as demand aggregation through group purchase organizations, efﬁcient data
processing and analysis and item standardization have garnered the attention of the biggest
health-care companies in the country in an effort to improve supply chain operations
(Michigan State University, 2019).
The Air Force Medical Service (AFMS) currently manages a $1.3bn contingency medical
programme comprised of over 5,100 assemblages across the globe at 87 unique locations
(JMAR, 2019). According to the Air Force Medical Logistics Guide, this programme supports
the capabilities of medical units in contingency situations such as home station medical
response, deployments and humanitarian efforts (AFMOA/SGAL, 2017). A critical element
of contingency medical assemblages are pharmaceutical items, which account for over
$113m of the programme (JMAR, 2019). A crucial subset of the overarching contingency
medical programme, and a primary focus of this research, are AD WRM assemblages.
These assemblages are durable and transportable kits that provide necessary medical items,
including medical supplies, equipment and pharmaceuticals to accomplish deployment or
mobility objectives (AFMOA/SGAL, 2017). Pharmaceutical items, as a component of AD
WRM assemblages, experience high turnover due to consumption or expiration, as items
routinely have a shelf life of only 24 to 36 months (AFMRA MLD, 2019). As a result, from an
enterprise-level, the Air Force Medical Readiness Agency (AFMRA), Medical Logistics
Readiness Support Branch, has observed shortages in material availability for many of
these pharmaceutical items (AFMRA MLD, 2019). The purpose of this research is to
identify, evaluate and apply optimal supply chain efforts to address shortages in the Air
Force Contingency Pharmaceutical Programme. Analysis of current contingency
pharmaceutical shortages shows a signiﬁcant trend of insufﬁcient, individual site demand
signals for various pharmaceutical items, resulting in non-fulﬁlment by private sector
suppliers. This research applies cost-beneﬁt analysis to evaluate various alternatives
through the theoretical scope of transaction cost economics.
Over 35% of all Air Force contingency medical assemblages and 21% of AD WRM
material assemblages, do not meet deployment requirement thresholds as deﬁned by
AFMAN 41–209 (JMAR, 2019). Deployment thresholds according to this guidance require
a minimum of 90% material availability of commodity items contained in the assemblage
(U.S. Air Force, 2019). A major driver of this shortfall is the inability to readily procure
contingency pharmaceutical items, which account for 41% of all contingency item
shortages across the entire contingency pharmaceutical programme (JMAR, 2019). Due to
the unpredictable nature of contingency operations many contingency pharmaceutical
items have non-recurring or non-usage demands, compared to a medical treatment
facility (MTF) day-to-day pharmaceutical demands which have established and frequent
usage patterns result from supporting a relatively predictable health-care environment
(AFRMA MLD, 2019). Due to military-speciﬁc uniqueness, the commercial industrial
sector requires known predictable demand signals. Consequently, without known
demand signals, order unfulﬁlment occurs for contingency items as Department of

Defense (DoD) contracted distributors are only obligated to fulﬁl items, which have
established usage demands (Defense Logistics Agency, 2013).
This contractual condition leaves the AFMS at a disadvantage in developing and
maintaining adequate inventories to support current and future requirements, which could
occur with the onset of contingency operations. According to the 2016 Defense Logistics
Agency (DLA) Medical Supply Chain report, DoD pharmaceutical item purchases through
DLA Troop Support make up only 1% of the entire US pharmaceutical industries’ market
share (Defense Logistics Agency, 2016). For this reason, the Air Force, as a DoD component,
must ensure that demand signals for contingency items are as robust as possible to ensure
adequate supply for required inventories. Ultimately, inefﬁciencies and shortfalls of
contingency item supply chains could directly impact our Nations’ readiness in military and
humanitarian operations. The research will address the following questions:
RQ1. What are the strategic supply chain integration efforts that can be used to remedy
current shortfalls?
RQ2. What are the costs and beneﬁts of possible strategic supply chain integration
efforts?
The structure of this research paper is as follows. Firstly, the theoretical scope of transaction
cost economics is reviewed to provide the research basis for the assessment of contingency
item procurement processes. The theory and background section also evaluates current
contingency medical processes in the AFMS, introduces the concept of cost-beneﬁt analysis
and highlights principles of strategic sourcing. Subsequently, the data collection practices of
this research and methodological applications of cost-beneﬁt analyzes are outlined. Finally,
ﬁndings are outlined with a discussion on research limitations and areas for future research.
Theory and background
Transaction cost economics
The review of applicable literature and theory for this research begins with a description of
transaction cost economics. Next, procurement procedural aspects will be covered, followed
by some strategic sourcing principals. Firstly, the basic premise of transaction cost
economics theory instantiates that individuals or ﬁrms seeking to make the best possible
decisions for their organization. This theory holds that organizations select speciﬁc
products, goods or services over alternatives due to the economization, optimization or
minimization of transaction costs (Williamson, 1979). In transaction cost economics theory,
the unit of analysis is the singular transaction (Williamson, 2010). A transaction in this
theory is deﬁned as an economic exchange of a good or service from a provider to a separate
user (Pint and Baldwin, 1997). Transaction costs can arise from a litany of organizational
functions and actions, including sourcing selections, contract management and performance
measurements (Pint and Baldwin, 1997). More speciﬁcally, transaction costs have been used
to represent inputs related to searching, contract development, ex-ante and ex-post
contractual actions, monitoring, retribution and resource acquisition activities (Rindﬂeisch
and Heide, 1997).
As organizations usually operate in resource-constrained environments, it is paramount
that they make economically efﬁcient decisions in charting future ﬁnancial and operational
decisions (Mahoney and Ketokivi, 2015). As the AFMS is not immune to this prevalence of
constrained operating environments, their business practices are highly suitable for
evaluation through a scope of transaction cost economics. Limited budgets, constraints on
contracting and purchasing avenues and the unpredictable nature of military operations fuel
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the often constrained environment of Air Force procurement. These decisions in constrained
environments can range from organizational structure constructs, personnel conﬁguration
or purchasing efforts; however, all focus on a key idea of managing relationships and
transactions to minimize waste while simultaneously creating value (Mahoney and Ketokivi,
2015).
Throughout the evaluation of transaction cost economics, the theme of bounded
rationality emerges as a key concept. Bounded rationality implies that there are limits to
time, control and information throughout a system, which can result in suboptimal
decisions, actions and organizational principles (Simon, 1972; Williamson, 1979). This
means that entities of the system, including employees, processes and agreements, may
engage in or promote suboptimal behaviour, that can be detrimental to effective decisionmaking in operations (Pint and Baldwin, 1997). Bounded rationality is not a result of
incompetence or inability, but rather a product of the fact that humans have limitations that
inﬂuence actions and strategy (Williamson, 2010). Williamson (2010) describes that humans
are limited in their rationality due to complexities found in the business environment.
According to the theory of information processing, when there is uncertainty in a given task
or environment, there is a larger need for ensuring information processing to obtain desired
outcomes (Landale et al., 2017a, 2017b). Information processing can be improved through
multiple avenues, including lateral relationships to share information (Landale et al., 2017a,
2017b). Transaction cost economics suggests that when the resulting effects of bounded
rationality greatly inﬂuence organizational transactions, organizational integration efforts
or information sharing, could be used to ensure the value of transactions is captured (Pint
and Baldwin, 1997). This concept of integration, through the implementation of centralized
procurement procedures, will be further evaluated in this literature review.
Contingency item purchasing processes and shortfalls
There are undoubtedly various transaction costs associated with the procurement of
contingency pharmaceuticals, i.e. contractual, ordering, holding, personnel and facility costs,
etc. For the purpose of this study, the main transaction cost focussed on is the shipping of
material due to the data available. However, prior to the minimization of these costs and
maximization of value can be pursued, the initial processes of contingency item demand,
outlined in Appendix B, must be evaluated. The initial step of the planning process begins at
the operational planning (OPLAN) level where Combatant Commanders’ capability
requirements for medical assets are deﬁned and transferred to the Air Force Surgeon
General’s (AF/SG) Ofﬁce (HQ USAF/SG, 2013). These resulting OPLANs layout
requirements for medical necessities in contingency instances such as number and types of
beds based on projected casualty streams, number of personnel deployed in the area and
aeromedical evacuation projections (AFMRA/SG4M, 2019). From these OPLAN
requirements, the AF/SG publishes the Medical Planning and Programming Guidance
(MPPG) to determine future endeavours in contingency planning (HQ USAF/SG, 2013).
The MPPG, as the Air Force Medical community’s planning and programming guidance
document, ultimately determines the bottom-up requirements to support medical
programme priorities, such as WRM, in support of combatant commander requirements
(HQ USAF/SG, 2013). The process for putting the AF/SG vision, as outlined by the MPPG,
into action is the Readiness Requirements Planning and Resourcing Process (RRPR). In the
RRPR medical unit type code requirements are identiﬁed for these major OPLANs, which
creates the total demand list (TDL) (HQ USAF/SG, 2013). The TDL is the resulting product
of the RRPR that captures all combatant commander requirements, thus establishing the
demand for the system (HQ USAF/SG, 2013). The establishment of the TDL, from the

origins of the various OPLANs, concludes the planning phase of contingency item
procurement. Execution of this process begins with the Medical Requirements List (MRL).
The MRL is a conglomeration of all AFMS possible personnel and equipment
assignments, mission requirements and expansion capabilities (HQ USAF/SG, 2013).
Ultimately, this listing outlines where each required capability, as deﬁned by the TDL, will
be stationed and in what ﬁscal year the capability will be required (HQ USAF/SG, 2013).
Once requirements are distributed amongst Air Force locations, via the MRL, assemblages
are constructed, supported and replenished at dictated sites through established
procurement channels, including the Pharmaceutical Prime Vendor (PPV) contract.
Commodities needed for governmental operations are procured through private sector
contractors at a cost of nearly $400bn annually (Cohee et al., 2018). The PPV contract,
awarded through DLA, is the primary mechanism exercised for procuring contingency
pharmaceutical items. The contract was awarded in 2014 and consists of one 30-month base
period and three 30-month option periods, available through 2024 (Defense Logistics
Agency, 2019). In Fiscal year (FY) 19, the breakdown of contingency pharmaceutical
purchases shows the utilization of the PPV contract over 70% of the time in pharmaceutical
procurement actions (JMAR, 2019). A key outcome measure of various types of government
contracts is supplier performance (Landale et al., 2017b). Supplier performance in the
PPV contract is measured by fulﬁlment metrics. According to DLA, fulﬁlment rates for the
PPV contract typically range from 95–98% (Defense Logistics Agency, 2019). This
generalization was substantiated by obtaining access to information from the ﬁll rate
module managed by DLA. The average ﬁll rate for the FY19 was 96.19% (Defense Logistics
Agency Troop Support, 2019).
This ﬁll rate percentage will be used as a factor in the cost-beneﬁt analysis methodology
to calculate remedied shortage amounts. According to the contract statement of work, “the
PPV programme provides worldwide support to DoD customers [. . .] by providing
pharmaceutical and pharmaceutical related products. The PPV will provide War Readiness
Material (WRM) support” (Defense Logistics Agency, 2013, p. 31). After solicitation, the
contract was awarded to Amerisource Bergin Drug Corporation (ABC), designating them as
the primary supplier of pharmaceutical contingency items to the DoD (Defense Logistics
Agency, 2019). ABC services both CONUS and OCONUS contingency pharmaceutical
demands from its nearly 30 US distribution centres (Amerisource Bergin, 2015). All
geographical regions are serviced by ABC, with the exception of the states of South Dakota,
North Dakota and Minnesota. These states are serviced by the Dakota Drug Company under
the designation of the Upper Prairie Region through a separately awarded small business
contract (Defense Logistics Agency Troop Support, 2019).
Under the current contract, the primary supplier must maintain a ﬁll rate of 98% for all
orders predicated upon sufﬁcient usage demands (Defense Logistics Agency, 2013). This
distinction is highly important, as it identiﬁes that the ﬁll rate will only be inclusive of
products which meet usage requirements. Usage under the contract is deﬁned as an item:
Ordered by the ordering facility a minimum of once per month for a minimum quantity of one and
is in the Medical Master Catalogue (MMC). Usage data shall be provided by the customer (Defense
Logistics Agency, 2013, p. 40).

Providers of these pharmaceutical items are not government entities, and therefore must
make money, as proﬁt-seekers, in their efforts (Glas, 2017). To determine which customers
are in the suppliers’ best interest to serve, as many companies serve both private and
governmental clients, the attractiveness of customers is evaluated (Glas, 2017). In the theme
of customer attractiveness, it is apparent that usage requirements in the PPV contract act as
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usage or demand can allow companies to enhance their possible beneﬁts of purchasing
agreement execution (Glas, 2017). With the shortcomings discussed above through the PPV
contracts, it is clear that additional mitigating measures must be evaluated to address
current system issues.

116

Strategic sourcing principles – centralized purchasing through demand aggregation
Purchasing for organizations has shifted from a more transaction-oriented initiative to a
strategic oriented action (Landale et al., 2017a). The main aspect of this transformation is the
execution of strategic sourcing which brings purchasing and supply management
operations from a low-level process in a ﬁrm, to an impactful and high-level role in
organizational strategic planning efforts (Landale et al., 2017a). The items that companies or
governments procure are purchased to create value as a factor in production or meeting
organizational requirements (Tate et al., 2016). Given that ﬁrms are in most cases required to
make purchases to assist in their value creation proposition, strategic decisions must be
made on how purchasing will be conducted throughout the organization. In alignment with
the theory of transaction cost economics:
Given the considerable volume of resources involved, ﬁrms and governments always seek to
optimize procurement so as to deliver value [. . .] In pursuing such a goal often the ﬁrst important
decision is to choose between centralized and decentralized purchasing (Dimitri et al., 2006, p. 47).

Purchasing from a ﬁrm or organization perspective can take various shapes and is a
strategic decision that must be made to maximize the value of the system as a whole.
The three main purchasing systems include centralized, decentralized and hybrid
purchasing models (Dimitri et al., 2006). In a centralized purchasing model, decisions of
organizational procurement including determinations of what products to buy, how to best
navigate procurement channels and when to make purchases are managed by a single entity
in the organization (Dimitri et al., 2006). Advantages of centralized procurement structures
include large scale aggregation of requirements, reductions in effort duplication and more
effective supply strategies (Tate et al., 2016).
In a fully decentralized procurement model, purchases for the organization are dispersed
amongst different entities, who make more localized decisions of how, what and when to
make acquisitions (Dimitri et al., 2006). Clearly, there are inherent beneﬁts to this purchasing
structure. Decentralization of purchasing can be more responsive to the local units desires
and allow for a better understanding of local requirements (Tate et al., 2016). The third type
of procurement systems are the hybrid models. In a hybrid purchasing model, purchasing
decisions are made both centrally and locally depending on situational factors (Dimitri et al.,
2006). In this structure, units can either make localized purchases or communicate demand
and spending information to a centralized purchasing unit that can look for aggregation
opportunities leading to better fulﬁlment and cost savings (Tate et al., 2016). For instance,
small orders dispersed temporally may be unappealing to a manufacturer who is seeking to
batch its production to minimize cost and enhance proﬁts. Under the current procurement
architecture, decentralized ordering lends itself to the condition where temporally dispersed
orders are not economically attractive to manufacturers; however, in a centralized
procurement structure orders can be aggregated across a range of time to capture a holistic
enterprise level demand signal that can be economically batched thereby enhancing its
appeal to industry.
Before the turn of the century, companies in many cases made strategic decisions to
give individual business units more independence in terms of purchasing decisions

(Rozemeijer et al., 2003). With the shift in increased competition in the business
environment, these ﬁrms are now undergoing consolidation processes in their purchasing
strategies as they are recognizing the beneﬁts of pooling common requirements
(Rozemeijer et al., 2003). Organizations are now exhibiting this shift in a transition to
hybrid purchasing structures with centralized features that leverage sourcing beneﬁts of
the entire organization’s demand portfolio (Trautmann et al., 2009).
A challenge of implementing hybrid practices is clearly deﬁning purchasing boundaries
and policies. These boundaries involve determining which facets will fall under the
authority of a centralized purchasing location to maximize organizational-wide synergies
and which facets of the organization will exercise local procurement (Trautmann et al.,
2009). If organizations are able to overcome the challenges inherent in implementing more
hybridized purchasing structures, there are numerous beneﬁts. The main beneﬁt of
harnessing the capabilities of hybrid purchasing organizations are purchasing synergies.
Purchasing synergies are deﬁned as a resulting value from the combination of multiple
business units’ resources, information and knowledge in purchasing (Trautmann et al.,
2009).
A relevant example of purchasing synergies currently exhibited in the health-care
industry, are Group Purchasing Organizations (GPO). Demand aggregation practices
are widely applied and used in the health-care industry through GPOs. A GPO is an
established entity that health-care facilities or networks can join to purchase supplies,
pharmaceuticals and equipment. Joining the GPO leverages centralized procurement
beneﬁts because the GPO consolidates demand from all users and captures the
savings and efﬁciency of the larger volume; however, purchases are still made at the
hospital or health network level under the GPO agreements (Dobson et al., 2014).
There are numerous beneﬁts to procuring health-care items through a GPO, such as
greater economies of scale, volume purchasing, increased negotiating power and
reduced administrative costs (Dobson et al., 2014). The increased economies of scale
and volume purchasing result from the consolidation of various entities’ demand for
like items, which ultimately reduces transaction costs. Because of the beneﬁts of
GPOs, it is estimated that between 96% and 98% of US Hospitals use GPO’s in their
procurement mix (Dobson et al., 2014).
As discussed previously in the medical contingency procurement process, the Air
Force primarily obtains items through the DLA established PPV contract. The
purchasing of required items for each location, based on requirements, is done on a
site by site basis at the 87 separate stock record account number locations. These
accounts do contain a mix of other sub-accounts, within their portfolio, however, they
are still ordered and maintained at the main location. For example, Wright Patterson
Air Force Base supports 20 organizations assigned under their account. Of these 20
accounts, 19 are ordered from and physically located at Wright Patterson Air Force
Base. Contingency items are maintained at the primary location and only sent to
external locations if required (WPMC WRM, 2019). Therefore, this procurement
system operates in a decentralized manner, with 87 main locations reporting demand
to distributors to obtain pharmaceutical items for their site. The research and
ﬁndings of this research will provide justiﬁcation for the recommendation of
transitioning to a model that maintains the local sites’ abilities to procure more
standard use items through government contracts at their own discretion while
harnessing the power of centralized purchasing models through demand aggregation
to remedy contingency item shortages in the Air Force.
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Methodology
Data collection and model construction
The primary data source for this cost-beneﬁt analysis is the Joint Medical Asset Repository
(JMAR). According to the Defense Health Agency, JMAR is, “a web-enabled repository that
captures inventory and transactions from distributed medical logistics systems at over 400
locations and provides ﬂexible reporting on materiel inventory, status, movement and
location” (Defense Health Agency, 2018). This data repository breaks down contingency
medical assets by service component and allows for a thorough analysis of the current
AFMS Contingency Pharmaceutical Programme, with the granularity to drill down to
individual locations and assemblage component items. Other pertinent information was
gathered from the Medical Contingency Requirements Workﬂow (MCRW) and AFMRA
MRL. Through integrations of raw data and generated reports from these platforms, the
current state of the AFMS Contingency Pharmaceutical Programme can be illustrated.
After depicting the current pharmaceutical item shortages in the AD WRM portfolio, the
model for this research was constructed. Pharmaceutical items shortages were aggregated
based on the item’s prime equivalent (PE) identiﬁcation number, evaluated for PPV contract
availability and ﬁnally assessed for minimum usage thresholds. Upon completion of this
evaluation, there were 646 unique pharmaceutical items that exhibited sufﬁcient usage
demand upon aggregation (JMAR, 2019). Ultimately, the purpose of this model construction
is to establish all pertinent information necessary to conduct the costs beneﬁt analysis.
Cost-beneﬁt analysis
A cost-beneﬁt analysis is a methodology for accurately assessing policies or projects based
on their associated impacts, in terms of beneﬁts and costs, that are valued in monetary terms
(Boardman et al., 2011). Cost-beneﬁt analyzes are a common evaluation tool in military
environments used to shape national security, set acquisition policies and direct investments
in service and supply procurement (Melese et al., 2015). According to Boardman et al. (2011),
there are three types of cost-beneﬁt analyzes, including ex-ante, in medias res and ex post. Ex
ante analyzes evaluate new initiatives that could possibly be implemented in the future
(Boardman et al., 2011). In medias res, analyzes are actually conducted during the life of a
current project, while ex-post analyzes are completed after a project has been completed or
retired (Boardman et al., 2011). The current contingency pharmaceutical procurement
programme, supported primarily through the DLA PPV contract, will be analyzed through
an in medias res cost-beneﬁt analysis as the contract is still valid with options for
continuation through 2024 (Defense Logistics Agency, 2013). In looking outside of the scope
of current contracting vehicles, the ﬁndings of this cost-beneﬁt analysis could also provide
useful insight for future solicitations of DoD contingency item contracts.
An in medias res cost-beneﬁt analysis can be accomplished through the navigation of the
following steps:
� speciﬁcation of alternative projects,
� identiﬁcation of project stakeholders,
� determination of costs and beneﬁts,
� quantitative prediction of impacts over the life of the project, monetization of
impacts, discounting of beneﬁts to obtain present values,
� computation of the present value of each alternative,
� sensitivity analysis, and
� crafting of ﬁnal recommendations (Boardman et al., 2011).

For the purposes of this research, as the data provided encompasses single year contingency
pharmaceutical procurement values, the steps of monetization of impacts, discounting of
beneﬁts to obtain present values and computation of the ﬁnal present values will be
compressed into a single step designated as monetization. The resulting steps are illustrated
below and will be used as this research’s methodological framework to evaluate and
compare alternative actions (Figure 1).
Step 1
The ﬁrst step of the cost-beneﬁt analysis is to clearly identify all possible options that could
be undertaken in the given environment. In this ﬁrst step of identifying alternative projects,
the wide array of possible options must be deﬁned and limited, as in most cases, there are a
large number of viable options (Boardman et al., 2011). Within this set of alternatives, the
current status quo or instance of no change should also be fully evaluated. Status quo
information is needed to compare the current project to hypothesized options to determine if
a new course of action, with its associated costs and efforts, should even be attempted
(Boardman et al., 2011). In the methodology section, the status quo and possible alternative
actions, with varying applications of centralized procurement, are deﬁned.
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Step 2
Following the deﬁnition of alternatives, stakeholders need to be properly identiﬁed.
Identiﬁcation of these stakeholders can be difﬁcult to delineate and scope down to a relevant
level for the given analysis being undertaken (Boardman et al., 2011). Projects can often be
analyzed from a focussed level excluding higher level or external stakeholders who may
have a more global perspective (Boardman et al., 2011). Therefore, it is critical to evaluate
possible stakeholders fully and then scope based on the level of connection to the project. In
the AFMS contingency procurement model, certain beneﬁts, as well as costs, could be felt at
a local base level; however, there are likely additional costs and beneﬁts that are realized at
the enterprise level. Once all relevant stakeholders of the project are identiﬁed and informed,
the costs and beneﬁts of the project must be evaluated.
Step 3
Evaluating the costs and beneﬁts of a project are ﬁrst done by identifying the physical
impact categories of the possible alternatives (Boardman et al., 2011). The term impacts
include the inputs and outputs of a project, which are then cataloged as either a cost or a
beneﬁt to the project (Boardman et al., 2011). Boardman et al. (2011) provide a framework of
identifying a cause and effect relationship between physical outcomes of the project and the
affected parties. If there is a correlation between stakeholder action and the outcome of the
system, there is likely an impact category that can be identiﬁed as a beneﬁt or a cost
(Boardman et al., 2011). These resulting beneﬁts and costs then need to be measured in some
form of units. The method for measuring each impact is usually based upon the data from
which the project is evaluated (Boardman et al., 2011). This means if there is monetary
information, the resulting impacts will likely be measured in increased proﬁt or cost

1) Alternave Projects

2) Stakeholder
Idenﬁcaon

3) Determinaon of
Impacts

4) Impact Predicon

5) Monetezaon

6) Sensivity
Analysis

7) Recommendaon

Figure 1.
Cost-beneﬁt analysis
process
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avoidance; however, there are many ways that impacts can be measured, including time
savings or operational efﬁciency improvements (Boardman et al., 2011).
Step 4
After impacts have been identiﬁed, the task is to then predict the impacts over the life of the
project (Boardman et al., 2011). Based on the calculated costs and beneﬁts, the analyst needs
to tie the impacts to a quantiﬁable output. The purpose of a cost-beneﬁt analysis is to assess
alternative courses of action which require prediction of outcomes supported by accurate
data (Boardman et al., 2011). The methodology section of this research will apply data
analysis of current information to predict the impacts of different project implementations.
Beneﬁts resulting from changing processes, compared to current operations, can be
analyzed through the in-media res cost-beneﬁt analysis.
Step 5
Once cost and beneﬁt predictions are established, it is important to assign monetary values
to effectively compare outcomes as options may have different costs and beneﬁts that
cannot be compared on a direct unit level. Effectively monetizing values can allow for
interpretation and comparison of results as it gives differing impacts similar units
(Boardman et al., 2011). In some cases, it is relatively simple to apply a monetary value to an
impact, such as instances of cost avoidance; however, in many occurrences, these monetary
evaluations are not easily constructed. This is especially true in the military or defense
environment.
In these instances where monetization is not straight forward, Boardman et al. (2011)
advocate for avoiding the reinvention of established practices through the use of the plugin
or estimated values when available. There is no silver bullet in connecting resulting outputs,
such as increased material availability, with quantitative, economic inputs, such as money
spent. However, a mechanism for quantifying the resulting impacts in military or defense
situations is proposed in the military production function, which attempts to quantify
defense outputs based on monetary inputs (Hartley and Soloman, 2015). According to
Hartley and Soloman (2015) “defense outputs involve a complex set of variables concerned
with security, protection and risk management [. . .] unlike private markets there are no
precise beneﬁt measures for defense output” (p. 44). Inputs, such as cost of procurement, are
more easily identiﬁed and measured than resulting outputs, which in this research is
material availability of contingency pharmaceutical items (Hartley and Soloman, 2015).
Therefore a cost-beneﬁt analysis acts as a starting point to, “identify the costs of defense
and then ask whether defense provides at least a comparable level of beneﬁts in the outputs
produced” (Hartley and Soloman, 2015, p. 65). The methodology of this research will provide
an estimated ratio that attempts to quantify the level of beneﬁts, in the terms of increased
material availability, to the economic inputs, in terms of programmatic appropriations.
Step 6
After monetary values have been established for various impacts on the different project
sets, uncertainties of the process must be evaluated through sensitivity analysis. Using
sensitivity analysis allows users to evaluate possible what-if scenarios. Identifying possible
outcomes can increase conﬁdence in analysis or help to identify areas for further evaluation
to reﬁne conclusions bolstered upon the conducted analysis (Georgiev, 2015). Sensitivity
analysis can be conducted in numerous manners, all ranging in complexity and accuracy.
The sensitivity analysis methods that will be used in this research are partial sensitivity
analysis, which looks at how beneﬁts change when a single assumption is varied while

holding other aspects constant and maximum and minimum case sensitivity analysis,
which looks at the impact to beneﬁts when the most or least favourable assumptions are
applied (Boardman et al., 2011).
Step 7
Once sufﬁcient sensitivity analysis has been completed, the analyst can then make a
recommendation based on the project with the largest present value (Boardman et al., 2011).
It is important to remember that ﬁnal present values are established from estimates of
impacts and their resulting monetary values (Boardman et al., 2011). In many instances,
speciﬁcally in the military, there are multiple variables, with different weights, that can lead
to the selection of one project over another. This means that the completion of a cost-beneﬁt
analysis is only one input to the entire decision-making process. There are often other
contributing, and sometimes conﬂicting, factors such as politics, security or legal
requirements that can greatly inﬂuence ﬁnal decisions (Boardman et al., 2011).
Cost-beneﬁt analysis application
In the ﬁrst step of the cost-beneﬁt analysis, four alternative projects were deﬁned. The
alternative projects to be assessed in this research are, namely, the continuation of the status
quo, centralized purchasing at a single site, centralized purchasing at a single site for US
regions and ﬁnally, purchasing at various regional sites. The status quo is included as an
alternative to acting as a benchmark to determine if any resulting action should be taken in
an attempt to improve the system. Alternative 1 assesses the current situation at sites with
AD WRM shortages. In this alternative there will be no proposed changes to the
consolidation of demand and sites will continue to procure items on an individual basis.
Alternative 2 identiﬁes system-wide level shortage aggregation opportunities from a
single designated site to fulﬁll both USA and international site shortages. The site selected
for this central hub was Kelly Field in San Antonio, TX. When analyzing aggregated
demand for each site, Kelly Field had the largest aggregated shortage amount of
pharmaceutical items (JMAR, 2019). Through centralization at Kelly Field, transportation
instances would be minimized and the current consolidated storage and deployment centre
(CSDC) mission of Kelly Field best suits the demands of receiving, handling and
transporting large numbers of contingency medical items (Whitson, 2013). Alternative 3
mirrors the strategy and processes of alternative 2 but eliminates fulﬁlment of international
region areas in an effort to assess changes in fulﬁlment and transportation costs based on
the smaller distribution network. The thought process behind this change was that the
network could still capture the aggregated demand proﬁles of the sites in the US regions
while eliminating the international shipping costs that are required to ship procured items
from Kelly Field to various OCONUS locations. This process will still identify system-wide
level shortage aggregation opportunities at a single designated site, but only for the US PPV
regions of West, South and North. The centralized ordering site for this action will remain at
Kelly Field for the same justiﬁcations outlined in alternative 2.
Finally, the fourth alternative identiﬁes global shortage aggregation opportunities at
regionally designated sites. The sites selected for these regional hubs were designated by
the Prime Vendor regional delineations of West, South, North, Paciﬁc and Europe (Defense
Logistics Agency, 2013). In evaluating aggregated demand, the location with the largest
aggregated shortage amounts for each region were Travis AFB (West), McGuire AFB
(North), Kelly Field (South), Kadena AB (Paciﬁc) and Ramstein AB (Europe). Through
centralized purchasing at these locations resulting transportation occurrences would be
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minimized as these ordering locations already have the highest regional demand when
compared to peers.
Once alternative projects are fully deﬁned, in the second step of the cost-beneﬁt analysis
stakeholders need to be identiﬁed to ensure no relevant desires and limitations are
overlooked. Although the identiﬁcation of stakeholders in this cost-beneﬁt analysis will not
directly inﬂuence the calculated costs, it is important to identify these stakeholders from a
systems perspective. Starting at the most micro level, the ﬁrst stakeholder would be the local
account managing the various assemblages assigned to their unit under the MRL. It is
important to understand that there will be relatively incalculable individual transaction
costs at this localized level from the various coordination that will take place. This research
accounts for these resulting transaction costs as ﬁxed costs, as work would be done under
the current WRM service contract.
From the next stakeholder level, the higher headquarters or AFMRA level, these local
transaction costs may not be realized, but it is important to understand that enactment of
any of these alternative projects will likely place additional workload on the individual
units. At the higher headquarters level, there will need to be communication and guidance
with the sites conducting the centralized ordering in the form of what items are need to be
ordered, when orders need to be placed and, when items need to be distributed to the
demanding locations.
Following the construction of alternative actions and stakeholder delineation, step three
of the cost-beneﬁt analysis outlines the costs and beneﬁts of the project. Relevant costs to be
assessed in this analysis include acquisition costs of procuring shortage items and
transportation costs of shipping the procured items from the centralized ordering site to the
demanding site. Acquisition cost as an impact to this cost-beneﬁt analysis will be calculated
by aggregating the shortage of each item to ﬁrst determine the amount required. Once the
shortage amount of each pharmaceutical item is determined, the acquisition cost is
determined by multiplying the remedied shortage amount by the cost per unit established
by the PPV contract.
Individual item weight information is maintained in the MCRW portal. Weights, in
pound increments, were gathered for each of the shortage items to establish a baseline
estimate for total weight shipped in each alternative project. The average weight of the
assessed items was 2.6 pounds, which was conservatively rounded up to 3 pounds for
shipping cost calculations. Shipping costs for three-pound shipments were then gathered
from third party logistics (3PL) companies FedEx and DHL. These 3PL companies are the
current Air Force shipping intermediaries for contingency pharmaceutical items. Estimated
shipping rates used to calculate transportation costs were established by gathering shipping
quotations for 3-pound shipments from Kelly Field to each unique site. From the 60 unique
shipping quotations, it was determined that the average domestic shipping cost was $12.02
for a three-pound shipment and the average international shipping cost was $103.94 for a
three-pound shipment (JMAR, 2019). These values were then proportionally applied to the
breakdown of anticipated domestic and international shipping amounts, which were 72%
and 28% of shipments, respectively (JMAR, 2019).
This resulted in an estimated 3-pound shipping rate of $37.30. This calculation of $37.30
per shipment is conservative in nature because shipping costs from the 3PL companies are
not directly linear when looking at pound increments. This means that a 3-pound domestic
shipment, costing roughly $12.02, would not jump to $24.02 for a shipment of 6 pounds. In
fact, a 6-pound shipment from Kelly Field to Wright Patterson AFB, as an example, would
only cost $16.64, which less than a 40% price increase from the shipment containing only 3

pounds. This means that consolidated shipments of larger total weights could further
optimize total transportation costs.
The primary beneﬁt to be assessed in this cost-beneﬁt analysis is remedied shortage
units which will impact the material availability percentage. Shortage units will be remedied
through the demand aggregation at single and regional ordering sites. The remedied
shortage amount is ﬁnalized by applying a coefﬁcient of 0.9619, as the average fulﬁlment
rate for the contract in FY19 was 96.19%. This reﬁnement accounts for the fact that
although there will be newly generated adequate demand proﬁles, the contract likely will
not fulﬁl 100% of the requests.
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Results and analysis
The results and analysis of this research continue the cost-beneﬁt analysis through step four
of impact prediction and quantiﬁcation. The completion of this step facilitates the
comparison of various alternatives identiﬁed earlier in the methodology. Through
integrations of raw data and generated reports from these platforms, the current state of the
contingency pharmaceutical programme can be illustrated. The compiled data shows that
the AD WRM programme is made of 2,533 assemblages, 21% of which do not meet AFMAN
41–209 deployment requirements (JMAR, 2019). These assemblages are programmed for
827k pharmaceutical items to meet demand requirements (JMAR, 2019). Of these 827k items,
there is a shortage of 158,139 items across 61 locations, resulting in a material availability
percentage of 80.8%. As demand streams are iteratively aggregated through the
progressive alternatives, the shortage of units dissipates. This is a consequence of order
batches exceeding the manufacturing providers contracted threshold to initiate order
fulﬁlment. The below table depicts resulting remedied shortage amounts and shipping
weights from the various alternatives (Table 1).
After impact prediction and quantiﬁcation are complete, the results are monetized for
further comparison. The ﬁfth step of monetization in this cost-beneﬁt analysis will account
for the resulting acquisition and transportation costs, deﬁned earlier, as well as monetized
values for resulting material availability. The monetary value of increases in material
availability was established using the principles of the military production function, which
quantiﬁes militaristic outputs based on monetary inputs (Hartley and Soloman, 2015).
The resulting beneﬁt ratio was calculated using the total AD WRM programmed
expense of $24.8m for pharmaceutical procurement. This means that the acquisition cost of
obtaining full material availability has a value of $24.8m based on contractually negotiated
pharmaceutical item prices. Therefore, the value of increased material availability is
calculated to be $248k/percent increase, which was calculated by dividing the $24.8m in
programmed expenses by total fulﬁlment. With this estimation, and applications of
previously discussed monetization of acquisition and transportation costs, the ﬁnal
monetization results of the cost-beneﬁt analysis are depicted below (Table 2).

Alternatives
1 – Status quo
2 – Single site procurement
3 – Single site procurement
(US regions)
4 – Regional site Procurement

Remedied
shortage units

Final shortage Shipping weight
units
(lbs.)

Increased
MAV(%)

Final MAV
(%)

No change
141,607
98,689

158,139
16,532
59,450

No change
258,745
184,462

No change
21.3
14.8

80.8
98.0
92.8

136,210

21,929

247,764

20.4

97.3

Table 1.
Impact predictions
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Table 2.
Cost-beneﬁt analysis
results with
monetization

Table 3.
Cost-beneﬁt analysis
of sensitivity
analysis

It was determined through additional research of the PPV contract that there are provisions,
which cover transportation expenses for intra-region shipping when orders are placed by a
Master Ordering Facility (MOF) within the same region (Defense Logistics Agency, 2013).
This ﬁnding was crucial to the estimations and presentations of transportation costs, as it
would eliminate many transportation expenditures when centralized orders are made intraregion.
Each of the designated ordering hubs, in all alternatives, are currently designated as
Master Ordering Facilities (AFMRA, 2019). The decrease in additional transportation costs
was accounted for South region orders in alternatives 2 and 3, as the designated centralized
ordering hub of Kelly Field is located in the South Region. Also, in alternative 4, the only
resulting transportation costs captured in this analysis arise from the shipment of items
from Travis AFB, in the West region, to the Upper Prairie region locations.
After monetization is conducted, the sixth step of sensitivity analysis is completed to
evaluate uncertainties or what-if scenarios of the alternative options. As these
pharmaceutical items are procured for uncertain contingency situations, current demand
could either decrease drastically in instances of contingency drawdowns or increase
substantially in situations where new conﬂicts or emergencies arise. The sensitivity
analysis for this research evaluates shifts in demand through Monte Carlo simulations,
conducted through the Microsoft Visual Basic Application (VBA). This code was
constructed to take small scale simulation efforts conducted on a single item to a platform
such as VBA, which automates the simulations for multiple items simultaneously. The VBA
code applied in this research simulates changes in demand patterns for all 1,124 shortage
items assessed in this research. Through base case, maximum case and minimum case
scenarios validity of the proposed consolidation methods in varying situations can be tested.
In the simulation, a standard deviation of 10% (s = 0.1) was applied to the AD WRM
platform’s authorizations for pharmaceutical items to account for possible variability in
future climates. Shifts in these factors were simulated 10,000 times for each item to allow for
determining maximum case (ramp-up) and minimum case (drawdown) what-if scenarios.
(Table 3)

Alternatives

Acquisition cost Transportation cost

1 – Status quo
2 – Single site procurement
3 – Single site procurement (US regions)
4 – Regional site procurement

No change
$ (3,544,601)
$ (2,038,018)
$ (3,033,908)

No change
$ (1,243,016)
$ (886,157)
$ (9,076)

Alt 4 simulation
results

Allow Remedied shortage Final shortage Shipping weight
Qty
units
units
(lbs)

Base case
Draw down (min
values)
Ramp up (max
values)
Average (mode)

824,294
506,839

136,210
68,970

21,929
30,401

1,143,028

163,723

821,980

115,867

Benefits

Net results

No change No change
$ 5,287,493
$ 499,875
$ 3,684,969
$ 760,793
$ 5,085,973 $ 2,042,988

Increased
MAV%

Final
MAV%

247,764
148,501

20.4
16.9

97.3
94.0

56,488

350,084

17.7

95.1

43,800

248,279

17.4

94.6

The outcomes of this sensitivity analysis, shown here for alternative four, highlights that
even in instances of varying and uncertain demand, proposed consolidation methods could
be highly beneﬁcial in terms of improving fulﬁlment. When looking at resulting costs, there
is some uncertainty, especially in “ramp-up” situations. Due to the conservative nature of
transportation cost estimates used in this research, the calculated transportation costs
reﬂect single item shipments with an average weight of three pounds. If optimized shipping
cost methods were used, for instance by increasing the weight amount of each shipment by
sending multiple items in a single shipment, the calculated value for transportation cost in
each ramp up situation would dramatically decrease and make what-if scenarios more
attractive in terms of net results.
Discussion
This research determined that there are strategic supply chain management efforts, mainly
demand aggregation and centralized procurement, which could be used at various levels of
implementation to mitigate the current AFMS contingency pharmaceutical procurement
shortfalls. The costs and beneﬁts of these supply chain principles were determined, and all
three proposed alternatives rendered a positive net value. While the primary focal point for
costs was related to shipping, other costs such as those pertaining to administrative and
ordering may render greater efﬁciencies not examined in this study. Regardless of decisions
made on which course of action to undertake, be it a full implementation of one of the
identiﬁed alternatives or a small scale implementation of aggregated purchasing for
strategically identiﬁed items, this research shows the positive effects of practicing
centralized ordering procedures based on demand aggregation of shortage items while
leveraging current practices and contractual purchasing agreements.
Enacting the principles of centralized ordering procedures for shortage items can lead to
over 20% increases in material availability of contingency pharmaceutical items. However,
as pharmaceuticals are only one subset of the medical contingency item platform, this
increased availability of pharmaceutical items is only one part of the availability issue
facing the AFMS in contingency item procurement. To improve the material availability of
the total AD WRM programme, additional efforts will need to be taken to diminish
shortages in the supply, equipment and repair item areas of the programme.
Managerial implications
The ﬁnal step of the cost-beneﬁt analysis is to provide a ﬁnal recommendation. After
determining the ﬂexibility of the PPV contract to use Master Ordering Facilities, which can
lower intra-region shipping costs, it is recommended to pursue alternative 4 which
advocates for regional procurement hubs across the globe. This alternative has the largest
net result as it capitalizes on transportation savings, while only experiencing minimal
decreases to fulﬁlment levels compared to a single source for the procurement of all items.
For instance, Alternative 4, which evaluates ﬁve regional procurement hubs, would
result in less remedied shortage items than a single procurement site. However, the
transportation savings resulting from intra-region transportation amount to 1m dollars.
Leaders would have to make the determination of the resulting unfulﬁled units from
alternative 4 is an acceptable shortage when the relevant savings are taken into account.
The use of the military production function, and assertion that each percent increase in
material availability renders $248k value, shows that the small difference in material
availability between Alternatives 2 and 4 likely would not be worth the cost of the increased
transportation expenses resulting from the single ordering and distribution point of
Alternative 2.
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Unless the resulting transportation costs of alternative 2 could be drastically minimized
through optimization of shipping processes, alternative 4 is determined to be the optimal
solution. Initial concerns in the conduction of this research were that moving from a single
centralized ordering point to the regional ordering site model would drastically diminish the
aggregated demand proﬁles, which would lead to decreased fulﬁlment levels. However,
breaking the demands down by region did not have a drastic impact on theoretical
fulﬁlment as hypothesized initially.
Limitations
There are numerous AFMS contingency programmes, as identiﬁed in the research problem
statement. The scope of this research focussed speciﬁcally on the 120 AD WRM deployable
UTC allowance standards. Therefore, the programmes of Home Station Medical Response
(HSMR), Force Health Protection (FHP), Mass Casualty First Aid Kits and MAJCOM speciﬁc
programmes were not evaluated in this research.
This research did not include and in-depth evaluation or shortage remediation of nonpharmaceutical contingency items, including contingency medical equipment, repair or
supply items. Other military services’ contingency pharmaceutical items, ordering policies
or, budgetary information was not assessed in this evaluation.
There are additional cost savings that could be leveraged such as contractual, ordering,
holding, personnel and facility costs. Due to the data set and scope of this research, these
other aspects were not included, which will likely lead to ﬁnancial implications through the
reduction of the required input to facilitate a disaggregated procurement architecture.
Future research should account for these aspects to provide greater ﬁdelity on this issue.
Future research
As contingency pharmaceutical items are only one aspect of the AFMS contingency item
programme, future research could be conducted to determine more effective ordering
policies for those non-pharmaceutical items including contingency medical supplies,
equipment and repair items. Completion of this research would provide a more robust for
necessary actions to fully mitigate all AFMS contingency item shortages. Future research
could also be addressed at a joint or Defense Health Agency (DHA), level comprised of
aggregated Army, Navy and Air Force data. Future shifts in military medicine practices,
administration and logistics will see programmes moving to a more joint service perspective
under the DHA. This would undoubtedly result in even larger demand signals, which could
further improve DoD material availability of contingency medical items.
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